For how we live.
A prespecified analysis of 131,276 older adults found RSVpreF cut RSV hospitalisations overall. In the immunosuppressed, baseline risk was nine times higher — but the subgroup was too small to prove it helped them.
A cohort at Kilifi County Hospital found RSV pneumonia killed 2.4% of admitted infants across 25 seasons, with no decline; severe undernutrition and congenital heart disease marked the highest risk.
The prequalification is about delivery, not efficacy: a cheaper, multi-dose presentation of RSVpreF meant to make large-scale rollout feasible where almost all RSV deaths occur.
The uncomfortable answer from the studies is that symptoms overlap too much to be sure without a test — and that most of what genuinely helps is prevention, not a cure.
JAMA published paired systematic reviews for the coming respiratory season. Both found vaccines reduced hospitalisation across age groups, with no new safety signals, though protection wanes over time.
Two pragmatic randomised trials and a Medicare nursing home cohort landed in the same week. Together they show real protection against hospitalisation and a durability question nobody has answered.
The American Academy of Pediatrics' 2026 schedule covers 18 diseases and carries 12 outside endorsements. The federal schedule signed three weeks earlier lists 11 vaccines for all children.
Seven of those nine were denosumab. The committee's September opinions also covered an RSV antibody for infants, a first EU treatment for IgG4-related disease, and four withdrawn applications.
A Federal Register notice on 9 June listed eleven vaccine topics and ten scheduled votes over three days. An amended notice on 24 June listed seven topics, three votes and two days.